Breaking News
Get 40% Off 0
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance Find Stocks Now
Close

Senti Biosciences Inc (SNTI)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Senti Biosciences's earnings

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
0.2809 -0.0181    -6.05%
24/04 - Closed. Currency in USD ( Disclaimer )
Pre Market
0.2872
+0.0063
+2.2428%
8:07:26 - Real-time Data
Type:  Equity
Market:  United States
  • Volume: 50,816
  • Bid/Ask: 0.0000 / 0.0000
  • Day's Range: 0.2803 - 0.2999
Senti Biosciences 0.2809 -0.0181 -6.05%

Senti Biosciences Inc Company Profile

 
Get an in-depth profile of Senti Biosciences Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

122

Equity Type

ORD

Senti Biosciences, Inc. operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma. It also develops SENTI-401, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer/CRC cells. In addition, the company develops Tumor-Associated Antigen and Protective Antigen Paired Discovery Platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells. The company has a strategic collaboration with Celest Therapeutics (Shanghai) Co. Ltd for the clinical development of SENTI-301A to treat solid tumors. Senti Biosciences, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

Contact Information

Address 2 Corporate Drive First Floor
South San Francisco, 94080
United States
Phone 650 239 2030
Fax -

Top Executives

Name Age Since Title
Susan D. Berland 68 2021 Senior Financial Executive & Independent Director
Martin Fussenegger - - Member of Scientific Advisory Board
Michael D. Varney 65 2021 Member of Scientific Advisory Board
James J. Collins 57 2021 Scientific Co-Founder, Chairperson of Scientific Advisory Board & Independent Director
Robin G. Taylor - 2021 Member of Scientific Advisory Board
Michael Andreeff - - Member of Scientific Advisory Board
Lawrence Fong - - Member of Scientific Advisory Board
Edward T. Mathers 63 2016 Independent Director
Wilson Wong - - Scientific Co-Founder & Member of Scientific Advisory Board
Michael Kalos - 2021 Member of Scientific Advisory Board
Timothy K. Lu 42 2016 Co-Founder, CEO, President & Director
Omid C. Farokhzad 54 2022 Independent Director
Ahmad Khalil - - Member of Scientific Advisory Board
Brenda G. Cooperstone 58 2019 Independent Director
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

SNTI Comments

Write your thoughts about Senti Biosciences Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Anthony Morrow
Note7Creole Nov 13, 2023 9:53PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
ER... 🤔
Carolina Echegoyen
Carolina Echegoyen Nov 12, 2021 8:39AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Does somebody know something about this stock?
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email